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Risk assessmentThere is continued interest in, and imperatives for, the classiﬁcation of contact allergens according to
their relative skin sensitising potency. However, achieving that end can prove problematic, not least
when there is an apparent lack of concordance between experimental assessments of potency and the
prevalence allergic contact dermatitis as judged by clinical experience. For the purpose of exploring this
issue, and illustrating the important considerations that are required to reach sound judgements about
potency categorisation, the lower alkyl methacrylate esters (LAM) have been employed here as a case
study.
Although the sensitising potential of methyl methacrylate (MMA) has been reviewed previously, there
is available new information that is relevant for assessment of skin sensitising potency. Moreover, for the
purposes of this article, analyses have been extended to include also other LAM for which relevant data
are available: ethyl methacrylate (EMA), n-butyl methacrylate (nBMA), isobutyl methacrylate (iBMA),
and 2-ethylhexyl methacrylate (EHMA).
In addressing the skin sensitising activity of these chemicals and in drawing conclusions regarding rel-
ative potency, a number of sources of information has been considered, including estimates of potency
derived from local lymph node assay (LLNA) data, the results of guinea pig assays, and data derived from
in silico methods and from recently developed in vitro approaches. Moreover, clinical experience of skin
sensitisation of humans by LAM has also been evaluated.
The conclusion drawn is that MMA and other LAM are contact allergens, but that none of these chem-
icals has any more than weak skin sensitising potency. We have also explored here the possible bases for
this modest sensitising activity.
Finally, the nature of exposure to LAM has been reviewed brieﬂy and on the basis of that information,
together with an understanding of skin sensitising potency, a risk assessment has been prepared.
 2014 The Authors. Published by Elsevier Inc. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
It is now well established that contact allergens vary consider-
ably (and by up to 5 orders of magnitude) with respect to their
relative skin sensitising potency. As a result there has been consid-
erable interest in the categorisation of chemical allergens with
respect to potency (Kimber et al., 2001). However, although this
is a legitimate aim, and a potentially very useful development, clas-
siﬁcation of chemical allergens in this way is not without problems.
It is necessarily the case that relevant data should be available that
provide a sound evidential basis for differential categorisation.
However, it is appropriate, in addition, to distinguish carefully
between potency and prevalence. That is, an important potentialconfounder is that there may be a lack of apparent concordance
between estimates of potency derived from experimental assess-
ment of skin sensitising activity and reports of prevalence of allergic
contact dermatitis (ACD) that derive from clinical experience. To
explore these issues, and to illustrate the important considerations
that need to be addressed, the skin sensitising activity of methyl
methacrylate (MMA) and other lower alkyl methacrylate esters
(LAM) have been reviewed.
Methyl methacrylate is an a/b-unsaturated monomeric ester
that is produced in relatively high volumes and used in a number
of industrial applications and consumer products (ECETOC, 1995).
This chemical forms part of a series of lower alkyl methacrylate
esters (LAM) that includes as well as MMA, ethyl methacrylate
(EMA), n-butylmethacrylate (nBMA), isobutylmethacrylate (iBMA)
and 2-ethylhexyl methacrylate (EHMA). The chemical structures
and key physico-chemical properties of the LAM considered in this
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sensitisation has been considered previously. It is acknowledged
that MMA has the potential to cause skin sensitisation resulting
in ACD (Betts et al., 2006), but, although it is associated with respi-
ratory irritation, the available evidence indicates that MMA fails to
cause sensitisation of the respiratory tract and allergic asthma
(Borak et al., 2011).
For purposes of this article the skin sensitising properties and
potency of MMA will be reviewed using new and previously avail-
able data, and this analysis will be extended to embrace also a sim-
ilar assessment of EMA, nBMA, iBMA and EHMA. For the purposes
of exploring the assessment of potency for the purposes of classiﬁ-
cation, the LAM provide a relevant case study, not least – for exam-
ple – because of the recent assessment of MMA by the American
Conference of Government Industrial Hygienists (ACGIH). In 2013
the ACGIH published a draft notice of change that identiﬁed
MMA as a potent skin sensitiser (ACGIH, 2013). Although, on the
basis of further review, that assessment was rescinded, the original
proposal does serve to illustrate the potential difﬁculties in deriv-
ing accurate assessments of skin sensitising potential when there
are apparently inconsistent data available.
1.1. Skin sensitisation and allergic contact dermatitis: the importance
of potency, hazard characterisation and risk assessment
Skin sensitisation resulting in allergic contact dermatitis is the
most common manifestation of immunotoxicity in humans, and
an important occupational health issue. In fact, there are many
hundreds of chemicals that have been identiﬁed as having skin
sensitisation potential sufﬁcient to cause ACD (De Groot, 2008).
Considerable progress has been made in developing a more
detailed, but as yet incomplete, understanding of the cellular and
molecular events that result in the acquisition and orchestration
of skin sensitisation, and in the elicitation of ACD (Martin et al.,
2011; Kaplan et al., 2012; Kimber et al., 2012; Ainscough et al.,
2013). That increased understanding of the immunological and
biochemical processes that cause skin sensitisation have, in turn,
paved the way to improved methods for toxicological evaluation
(Kimber et al., 2011). Naturally, the development of accurate risk
assessments requires, in addition to effective hazard characterisa-
tion, a clear appreciation of likely considerations of exposure. The
importance of exposure considerations in the context of LAM is
explored later in this review.
The initial approach to the identiﬁcation of skin sensitisation
hazards made use of guinea pig test methods in which activity
was measured as a function of visual assessment of challenge-
induced skin reactions in animals exposed previously to the test
chemical. The guinea pig tests most thoroughly evaluated and
most commonly used were the guinea pig maximisation test
(GPMT) and the occluded patch test (Magnusson and Kligman,Table 1
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Boiling point (C) 100.36 118.2 1
Vapour pressure (hPa at 20 C) 37 20 2
Water solubility (g/l @ 20 C) 15.3 4.69 0
Partition coefﬁcient n-octanol/
water (log value)
1.38 1.87 31969; Buehler, 1965). These methods served the toxicology com-
munity well, but were subject to a variety of limitations, not least
of which was the lack of an objective measure of sensitising poten-
tial. In an attempt to address some of those limitations the mouse
local lymph node assay (LLNA) was developed in which skin sensi-
tising chemicals are identiﬁed by their ability to provoke lympho-
cyte proliferative responses in lymph nodes draining the site of
topical exposure to the test material (Kimber and Weisenberger,
1989; Kimber et al., 1989). The LLNA was evaluated extensively
and was the subject of formal validation exercises. It is currently
the preferred method for the identiﬁcation of contact allergens
and has been used extensively for this purpose. A detailed consid-
eration of the LLNA is beyond the scope of this article, but there are
several reviews available that document the development, valida-
tion, acceptance and practical application of this method (Kimber
et al., 1994, 2002; Basketter et al., 2002; McGarry, 2007). Experi-
ence has shown that the LLNA provides a generally accurate and
reliable way of identifying skin sensitisation hazards, and com-
pared with the guinea pig tests that it largely superseded, offers
a number of important advantages.
However, reliable hazard identiﬁcation is only the ﬁrst step in
the toxicological evaluation of skin sensitisation potential.
Although considerations of potency are germane for all classes of
toxicants, this is of particular relevance for contact allergens that
are known to differ by up to 5 orders of magnitude with respect
to their relative skin sensitisation potency (Kimber et al., 2001).
Skin sensitisation potency is best deﬁned in terms of the
amount of chemical that is required to cause the acquisition of sen-
sitisation; the more potent the chemical allergen the smaller will
be the threshold exposure concentration required to induce skin
sensitisation. Although, in some instances it is possible to derive
estimates of sensitising potency from the results of guinea pig
assays, this is not always the case since such methods are not
normally conﬁgured to allow characterisation of dose–response
relationships during the induction phase of skin sensitisation
(Kimber et al., 2001).
In contrast, the LLNA has proven useful for characterisation of
the relative potency of contact allergens. This is due to the fact that
the end point used in the LLNA (proliferative responses by draining
lymph node cells [LNC] provoked by local topical exposure to a
contact allergen) is both causally and quantitatively related to
the effectiveness with which skin sensitisation will be acquired
(Kimber and Dearman, 1991; Kimber et al., 1999, 2012). The cen-
tral event in the acquisition of skin sensitisation is the activation
and clonal expansion of allergen responsive T lymphocytes within
lymph nodes draining the site of exposure to the chemical allergen.
Evaluation of proliferation by draining LNC induced by exposure to
chemical provides a convenient measure of this, and thereby of the
vigour and potency of the response (Kimber and Dearman, 1991;
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means of deriving an assessment of the relative sensitising potency
of contact allergens (Kimber et al., 2001; Kimber and Basketter,
1997). The approach used is to derive from dose response relation-
ships in the LLNA an EC3 value; deﬁned as the amount of test
chemical required to elicit a 3-fold increase in proliferative activity
compared with concurrent vehicle control values (Basketter et al.,
1999). The EC3 value has been shown to provide a reliable measure
of skin sensitising potency (Warbrick et al., 1999; Basketter et al.,
2007a,b). Importantly, there is a close association between EC3 val-
ues derived from the LLNA and the relative potency of contact
allergens as judged by clinical experience (Basketter et al., 2000;
Gerberick et al., 2001). Moreover, it has been shown that there
exists a correlation between human skin sensitisation thresholds
and potency as determined through LLNA EC3 values (Basketter
et al., 2005; Schneider and Akkam, 2004).
The availability of a robust and reliable method for assessment
of relative skin sensitising potency is of considerable importance
for the classiﬁcation of contact allergens and for the development
of accurate assessments of risk (Kimber et al., 2001, 2003; Loveless
et al., 2010). Moreover, a quantitative measure of potency allows
for discrimination between the prevalence of ACD to a particular
contact allergen and its inherent sensitising potency. The two met-
rics are independent. Thus, in the US and Western Europe nickel is
regarded as a common allergen, and among the most prevalent
causes of ACD. However, nickel is not considered to be a potent
contact allergen, and is in fact a relatively weak sensitiser. The high
prevalence of ACD caused by nickel is not a reﬂection of skin sen-
sitising potency, but rather the widespread opportunities that exist
for exposure generally, and for intimate exposure in particular
(Kimber et al., 2002).
Recently, for a variety of reasons, there has been a considerable
investment in the development of alternative (non-animal) meth-
ods for the assessment of skin sensitising activity. Among the gen-
eric approaches that have attracted interest are the following: (a)
peptide reactivity assays for the identiﬁcation of sensitising chem-
icals as a function of their inherent or acquired electrophilicity and
the ability to form stable associations with protein (Natsch et al.,
2007; Gerberick et al., 2009), (b) models of (quantitative) struc-
ture–activity relationships ([Q]SAR) Aptula et al., 2005; Patlewicz
et al., 2007, and (c) various cell-based assay systems using most
commonly dendritic (DC)/DC-like cells or keratinocytes (Natsch
and Emter, 2008; Ashikaga et al., 2010; Ouwehand et al., 2010).
Some of these assays are approaching validation or have recently
been validated (JRC Scientiﬁc and Policy Reports, 2013), whereas
others are less well developed and should be regarded as work in
progress. It must be emphasised that the above list is by no means
exhaustive and that there are other methods, and other strategies,
for predictive testing that are currently being explored. The impor-
tant point is, however, that although some of the above approaches
may – in time – yield methods suitable for the identiﬁcation of
contact allergens, their ability to provide information about rela-
tive potency is much less certain. Although some progress is
reported, and interesting paradigms have been proposed (Jowsey
et al., 2006; Jaworska et al., 2013), experience to date indicates that
it will prove challenging to develop a method, or suite of methods,
that can provide an accurate assessment of relative skin sensitising
potency comparable with that available currently from the LLNA
(Basketter et al., 2012).
Against that background it is the case, therefore, that for the
purposes of exploring the sensitising potency of contact allergens
the most useful information derives from LLNA EC3 values, and
such data will provide an important element of the consideration
here of the skin sensitising properties of LAM. However, although
the most direct evidence of potency is provided by the LLNA, it
has to be acknowledged that other methods, including guinea pigpredictive tests, certain in silico and in vitro approaches, and clinical
experience, can all provide information that may contribute to a
holistic appraisal of skin sensitising activity. Accordingly, all
relevant sources of information will be included here for the pur-
pose of exploring as a case study the skin sensitisation properties
of LAM.
1.2. The lower alkyl methacrylate esters: chemistry and applications
Acrylic resins are thermoplastic polymers produced by the
polymerisation of methacrylic acid esters (methacrylates), or
acrylic acid esters (acrylates). MMA is by far the most important
methacrylic acid ester and in 2011 the global manufacture of poly-
methyl methacrylate resins was estimated to be approximately
3 million metric tons (Chemical Economics Handbook, 2012). The
market for EMA, nBMA, iBMA and EHMA is substantially smaller
than for MMA because these monomers are typically incorporated
in smaller amounts to modify the properties of the resulting
polymer.
The use of LAM esters in liquid form is considerably less
common although there are a number of important applications,
including use in the building industry (reactive resins and paints),
medical (bone cements) and dental (manufacture and repair of
dentures), and in arts and crafts (cements and embedding
systems).
1.3. Skin sensitisation potential and potency of lower alkyl
methacrylate esters
In examining the sensitising properties of LAM the approach
taken is to consider in turn the information available, from relevant
sources, for MMA, EMA, nBMA, iBMA and EHMA.2. MMA
MMA is the most extensively studied of these compounds. It is
well established that MMA has the potential to cause skin
sensitisation and allergic contact dermatitis (Guerra et al., 1993;
Rustemeyer and Frosch, 1996, 2000; Geukens and Goossens,
2001; Kassis et al., 1984).
2.1. LLNA
As indicated above, for the purposes of exploring the skin sen-
sitising potency of MMA, a key consideration is the availability of
data on EC3 values derived from the LLNA. A relatively recent
report by Betts et al. (2006) described the activity of MMA in the
LLNAwhen formulated either in acetone, or in a 4:1 mixture of ace-
tone: olive oil (AOO). In the same investigations comparisons were
made with 2,4-dinitrochlorobenzene (DNCB), a very potent contact
allergen. It is possible to record EC3 values in a number of ways: (a)
as the percentage of chemical (in vehicle) required to elicit a 3-fold
increase in LNC proliferative activity, (b) as the molar concentra-
tion of chemical required for a 3-fold response, or (c) as a function
of the concentration of chemical required per unit area of skin.
While it is the last of these that most accurately reﬂects the impor-
tant metric in the acquisition of skin sensitisation, all approaches
are legitimate in terms of evaluating relative potency. In the inves-
tigations reported by Betts et al. (2006) EC3 vales were recorded in
terms of the percentage of chemical in vehicle. When delivered in
acetone as vehicle MMA was found to have an EC3 value of 60%,
and when formulated in AOO to have an EC3 of 90%. These are high
EC3 values indicative of only weak skin sensitising activity. This is
illustrated by comparisons with the results obtained using DNCB in
the same series of experiments (Betts et al., 2006). As expected,
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EC3 value of 0.036%. Collectively these data serve to reinforce the
point made previously that contact allergens vary by several (up
to 5) order of magnitude with respect to their relative skin sensitis-
ing potency. In the experiments reported by Betts et al. the esti-
mated potency of DNCB in AOO as judged by EC3 value was
found to be greater than that of MMA in the same vehicle by a
factor of approximately 2500 (Betts et al., 2006).
As described above, the availability of EC3 values has prompted
proposals for the categorisation of contact allergens as a function
of their relative skin sensitising potency (Kimber et al., 2001,
2003; Loveless et al., 2010). One approach that has been suggested
is to adopt 4 categories as follows: Extreme Sensitiser (EC3 value of
less than 0.1%), Strong Sensitiser (EC3 value of less than 1%, but
greater than 0.1%), Moderate Sensitiser (EC3 value of less than
10%, but greater than 1%), and Weak Sensitiser (EC3 value equal
to, or less than, 100%, but greater than 10%). A non-sensitising
chemical would naturally not achieve an EC3 value (Kimber
et al., 2003). Employing those criteria to the data reported by
Betts et al. (2006) then DNCB would be considered to be an
extreme skin sensitiser. In contrast, MMA – whether formulated
in either acetone or AOO – would be categorised as a weak
sensitiser.
Recently, in comparative studies of the standard LLNA with a
version of the assay designed to avoid the use of radiolabelled thy-
midine for the measurement of LNC proliferation – the Lymph
Node Cell Counts (LNCC) approach – MMA was one of the chemi-
cals examined. In neither the standard LLNA, nor in the LNCC, did
MMA elicit a positive response for classiﬁcation as a sensitiser
(Basketter et al., 2012).
There is little other information regarding the sensitizing activ-
ity of MMA in mice. It is relevant to note, however, that in a report
published by Rustemeyer et al. (1998) the authors commented that
to their knowledge no successful attempts to induce skin sensiti-
sation to MMA in mice had by that date been reported. They com-
mented also that they had attempted to induce skin sensitisation
to MMA in mice using various procedures without success
(Rustemeyer et al., 1998).
2.2. Guinea pig assays
Attempts to induce skin sensitisation in guinea pigs have com-
monly been problematic. Although some success was reported by
Chung and Giles (1977), the results could not be reproduced by
other investigators using similar or different protocols (Parker
and Turk, 1983). Others have met with variable, and often very lim-
ited, success (Van der Walle et al., 1982; Nyquist et al., 1972;
Marzulli and Maguire, 1982). In an investigation designed to com-
pare various endpoints for assessment of skin sensitisation in gui-
nea pigs, MMAwas one of the chemicals evaluated. In that series of
experiments MMA failed to induce sensitisation (measured as a
function of challenge-induced skin reactions), and also failed to
cause lymph node activation (Bull et al., 1985).
In studies using a standard GPMT, Boman et al. (1996) found
that sensitisation could be induced with MMA but only with com-
paratively high test concentrations. An induction regime employ-
ing 10% of MMA for both intradermal injection and epicutaneous
exposure resulted in each of 5 guinea pigs displaying reactions
when animals were challenged subsequently with 100% of MMA
(Boman et al., 1996).
A detailed summary in tabular form of guinea pig skin sensiti-
sation assays conducted with MMA is available elsewhere (Borak
et al., 2011). The authors of the article in which that table appears
drew the general conclusion that results indicate weak sensitisat-
ion potential, with a signiﬁcant proportion of tests giving negative
results. The same conclusion is drawn here.2.3. In vitro and in silico approaches
A wide variety of approaches for the development of alternative
(non-animal) methods for the identiﬁcation and characterisation of
skin sensitising chemicals are currently being explored. Some of
these methods are more fully developed and evaluated than others,
and it is upon these that attention will focus primarily here. For the
purposes of this article the methods that will be considered are as
follows:
(a) Direct Peptide Reactivity Assay (DPRA) (JRC Scientiﬁc and
Policy Reports, 2013; Gerberick et al., 2004) in which the
inherent electrophilicity of test chemicals is measured as a
function of their ability to associate with model peptides.
There has, more recently, been described a modiﬁcation of
the standard DPRA that seeks to facilitate the detection of
pro-haptens that require metabolic activation to form an
electrophilic species. This modiﬁed assay incorporates
horseradish peroxidise and hydrogen peroxide to effect
pro-hapten conversion; the so-called Peroxidase Peptide
Reactivity Assay (PPRA) (Gerberick et al., 2009). However, in
the context of LAM, the more relevant conﬁguration of the
test is the DPRA since the parent esters are inherently elec-
trophilic, and therefore complete haptens in their own right.
(b) Assays based on the activation of DC or DC-like cells. One
such test that has received considerable attention is the
human Cell Line Activation Test (h-CLAT) in which the ability
of test chemicals to induce increases in the expression of
speciﬁc plasma membrane determinants (CD54 and/or
CD86 that are markers of activation on DC) on a human
monocytic leukaemia cell line (THP-1) is measured
(Ashikaga et al., 2010; Sakaguchi et al., 2006; Nukada
et al., 2012). Another assay system, that employs a very sim-
ilar approach and uses the human myelomonocytic cell line
U-937, is the Myeloid U-937 Skin Sensitization Test (MUSST)
(Ade et al., 2006; Python et al., 2007). The readout most
commonly used is an elevated expression of CD86. Finally,
brief mention will be made of a series of experiments in
which the impact of chemicals on a variety of activation
markers were examined using human blood monocyte-
derived DC (Rustemeyer et al., 2003). All such assays are
intended to reﬂect in vitro the ability of contact allergens
to provoke the activation and maturation of DC within the
skin.
(c) Approaches based on signalling pathway activation. One
such is the KeratinoSens™ assay (Natsch and Emter, 2008;
Natsch, 2010; Emter et al., 2010) which is predicated on an
appreciation of the nuclear factor-erythroid 2-related factor
2 (Nrf2)-Kelch-like ECH-associated protein 1 (Keap1)-anti-
oxidant response element (ARE) pathway. Keap1 is a protein
sensor that possesses cysteine (Cys) residues that are highly
reactive with many electrophilic sensitising chemicals.
Covalent modiﬁcation of these Cys residues by contact aller-
gens causes Keap1 to dissociate from Nrf2 which then accu-
mulates in the nucleus causing the transcriptional activation
of genes with an ARE in their promoter regions. The Kerati-
nosens™ assay uses a keratinocyte-based luciferase reporter
cell line to measure activation of the Keap1/Nrf2 pathway as
a function of induced gene transcription (Emter et al., 2010).
A very similar method similarly based on the activation of
Nrf2, the LuSens assay, has been reported also (Bauch et al.,
2012).
(d) In silico approaches that are based on an understanding of
the relationship between physicochemical properties and
skin sensitisation potential. There is a very substantial liter-
ature on (Q)SAR/SAR approaches (Aptula et al., 2005;
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might provide a platform for potency assessment as well
as hazard identiﬁcation, there is probably still further devel-
opment required to achieve that (Teubner et al., 2013). One
of many approaches that has been used to identify structural
alerts for skin sensitisation is the OECD (Organisation for
Economic Cooperation and Development) QSAR tool box
(Version 2.0, 2010) (OECD, 2010).
Although there are other alternative methods that are being
explored, it is those approaches summarised above that have infor-
mation available regarding the skin sensitising activity of MMA.
There is limited experience withMMA in in vitro and in silico test
systems. The evidence available can be summarised as follows. In
theDPRAMMAhas been shown to yield a positive response, display-
ing binding to both Cys-peptides and Lys(lysine)-peptides (Bauch
et al., 2012). A positive response withMMA in the DPRA is also cited
in a separate report from the same group of authors (Bauch et al.,
2011; Kolle, 2013; Wiench et al., 2013). In a separate investigation
MMA gave comparable results in a DPRA, with a classiﬁcation of
moderate reactivity (CA Ryan; personal communication).
Data are available for the activity of MMA in the MUSST and
h-CLAT assays. In both a positive response was recorded, with only
weak reactivity being observed in the h-CLAT assay (Bauch et al.,
2012, 2011; Kolle, 2013; Wiench et al., 2013). The only other infor-
mation regarding the activity of MMA in a DC-based cellular assay
comes from investigations using human peripheral blood
monocyte-derived DC (Rustemeyer et al., 2003). In those studies
the impact of chemicals on a variety of DC activation markers were
examined: CD80, CD83 and CD86, CXCR4 and CCR5 (both
chemokine receptors) and P-glycoprotein (Pgp) and lung resistance
protein (LRP) (two multidrug resistance-related molecules). MMA
(which was characterised by the authors as being a weak sensitiser
based on clinical data and the results of guinea pig assays) was
found, in common with other contact allergens tested, to elicit
some increased expression of all markers examined, although in
the case of CD83 and LRP responses to MMA were weaker than
recorded with other allergens (Rustemeyer et al., 2003).
In the KeratinoSens assay, and in the very similar LuSens
method, MMA was initially reported to be negative (Bauch et al.,
2012, 2011). However, in subsequent studies reported elsewhere
MMA consistently tested positive in the LuSens assay (Kolle,
2013; Wiench et al., 2013), this being the result of continued devel-
opmental work with the method achieving increased sensitivity (R
Landsiedel; personal communication).
The picture that emerges for MMA in in vitro assay systems is of
positive responses (albeit sometimes relatively modest responses)
in the DPRA, h-CLAT and MUSST, and LuSens methods.
Finally, it is known that MMA is a direct acting Michael acceptor
electrophile, and on that basis is identiﬁed as a contact allergen in
the OECDQSAR tool box (OECD, 2010). In attempts to develop quan-
titative models for Michael acceptors it has been acknowledged
that MMA (and other short chain acrylates and methacrylates)
are, in reality, less potent sensitisers than predicted by the model
(Roberts and Natsch, 2009; Enoch and Roberts, 2013).
Taken together, the evidence available frompredictive testmeth-
ods and other experimental systems, including animal models and
in vitro and in silico assays, indicates that although MMA clearly
has some potential to cause skin sensitisation, it is not a potent con-
tact allergen. On the basis of the LLNA,MMAwould be classiﬁed as a
weak allergen (possessing only modest skin sensitising potency).
Although, for the reasons discussed above, estimates of skin sensiti-
sation potency are currently best furnished by EC3 values derived
fromthe LLNA, there are nodata available fromguineapig predictive
tests, in vitro assay systems or in silico approaches that would
contradict the view that MMA is a weak skin sensitiser.It is relevant, therefore, to consider brieﬂy whether the evidence
available from human studies and clinical experience serves to
support, or to contest, the view that MMA is not a potent contact
allergen.
2.4. Human studies and clinical experience
Case study reports of skin sensitisation have been summarised
and commented upon previously by Betts et al. (2006), in which
publication a list of reports was provided in tabular form. The data
summarised in that article revealed extensive variation between
the reports cited with respect to the number of subjects in whom a
positive responsewas observed as a function of those tested. In fact,
the prevalence was found to vary between studies from 0% to 16%
(Betts et al., 2006). The higher prevalence rates were reported in
those studies where relatively small numbers of patients with der-
matitis had been referred to clinic. The corollary was that much
lower prevalence rates were observed among larger cohorts, but
even in those cases it could be argued that the ﬁgures obtained are
an over-estimation of the frequency with which skin sensitisation
develops among populations exposed to MMA. The data of Pﬂug
(Pﬂug, 1995, 2000) were considered to perhaps provide the most
accurate reﬂection of the prevalence of sensitisation to MMA in
the dental industry (values of between 0.25% and 0.378%), although
even in these reports there is possibly some over-estimation of true
rates of sensitisation to MMA (Betts et al., 2006; Pﬂug, 1995, 2000).
The conclusion drawn at that time was that, although there was no
doubt that MMA is a contact allergen, the available evidence from
predictive test methods indicated relatively weak skin sensitising
potential. The data available from reports of skin sensitisation to
MMA among exposed human population was considered to be con-
sistent with that conclusion (Betts et al., 2006).
It is, of course, important to consider whether there are any
other data that have become available regarding human skin sen-
sitisation to MMA since publication of the Betts et al. article (Betts
et al., 2006). Little new information has emerged that is relevant to
the prevalence of sensitisation to MMA, or to its sensitising
potency. Goon et al. (2006) described an investigation of 1632 sub-
jects, comprising 1322 dental patients and 310 dental health pro-
fessionals. It was found that 2.3% of patients and 5.8% of health
professionals displayed positive patch test reactions to (meth)acry-
late allergens. The frequency of patch test responses to MMA was
low. Of the 2.3% of dental patients that showed positive patch test
reactions to any (meth)acrylate allergen, only 13.3% of that number
responded to MMA (equivalent to approximately 0.3% of the total
patient population). Similarly, of the 5.8% of dental health profes-
sionals that reacted to any (meth)acrylate, 38.8% were sensitised
to MMA, equivalent to approximately 2.2% (Goon et al., 2006).
In the absence of any other data that informs understanding of
human sensitisation to MMA there is no reason to revise the con-
clusions published previously (Betts et al., 2006). Based on all
available data it is concluded that MMA is a contact allergen, but
displays weak skin sensitising potential. The relatively low fre-
quency of sensitisation among those exposed to MMA is consistent
with that conclusion.
2.5. Conclusion
MMA is a contact allergen but has weak skin sensitisation
potential.3. EMA
EMA has not been investigated in the same depth as MMA, but
there are relevant data available.
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The activity of EMA in the LLNA has been reported recently. In a
standard assay, groups of mice were exposed to 25%, 50% or 100%
EMA in vehicle (AOO). At those doses, respectively, the recorded
stimulation indices were 0.93, 1.41 and 3.85. The EC3 value derived
from these data is 82.6%; a result that would categorise EMA as a
weak sensitiser (Dony and 2013. Ethyl methacrylate: local lymph
node assay in mice. Harlan Cytotest Cell Research GmbH (Harlan
CCR) Dony, 2013a).3.2. Guinea pig assays
Other than the report by Chung and Giles (1977) who appar-
ently enjoyed considerable success in sensitising guinea pigs to
several LAME (EMA, MMA and nBMA), experience suggests that
EMA at best elicits weak responses in guinea pigs. Studies employ-
ing the GPMT used increasing intradermal induction concentra-
tions of EMA (0.17 M, 0.50 M and 1.50 M), together with
epicutaneous exposure to 1 M EMA. Animals were subsequently
challenged with 3 M EMA. Only 1 in 10 animals responded to chal-
lenge following exposure to either 0.50 M or 1.50 M intradermal
EMA; no animals responded following induction with 0.17 M
EMA (Van der Walle et al., 1982). In another report of a commis-
sioned study using the GPMT a negative result was obtained with
EMA (Poole and 1980. Methacrylate dethyle (MAE). Test for contact
sensitisation potential in the guinea pig maximisation test. Consul-
tox Laboratories Ltd. (Poole et al., 1980) On the basis of those data
EMA would not be classiﬁed as a skin sensitiser in the GPMT; the
threshold response for classiﬁcation being 30%.3.3. In vitro and in silico approaches
EMA has been evaluated in several methods. In the DPRA EMA
tested positive with somewhat weaker activity than that observed
with MMA (Kolle, 2013; Wiench et al., 2013). EMA also elicited
positive responses in the LuSens assay and in the MUSSTT (Kolle,
2013; Wiench et al., 2013). In common with MMA, EMA is a direct
acting Michael acceptor electrophile, and on that basis is also iden-
tiﬁed as a contact allergen in relevant SAR models and the OECD
(Q)SAR tool box (OECD, 2010).3.4. Human studies and clinical experience
Skin sensitisation to EMA is most commonly associated with
artiﬁcial ﬁngernails and there are available in the literature a num-
ber of case studies that describe this. An illustrative example is
provided by Conde-Salazar et al. (1986). In a review of patch test-
ing with (meth)acrylates cited previously by Betts et al. (2006), it
was found that among patients with a history of exposure to meth-
acrylates and acrylates 7.4% of those tested reacted to EMA; exactly
the same percentage that was shown to be responsive to MMA
(Kanerva et al., 1997).3.5. Conclusion
Like MMA, EMA is a contact allergen. However, the available
evidence is that it has only modest (weak) skin sensitisation
potency.4. nBMA
It is also the case with nBMA that there are only limited data
available relevant for consideration of skin sensitising potency.4.1. LLNA
There is available a single report on the activity of nBMA in the
LLNA (Dony and 2013. n-Butyl methacrylate: local lymph node
assay in mice. Harlan Cytotest Cell Research GmbH (Harlan CCR)
Dony, 2013b). In a standard LLNA, groups of mice were exposed
to 25%, 50%, or 100% nBMA in vehicle (AOO). The stimulation indi-
ces recorded were, respectively, 2.19, 3.28 and 5.41. Derived from
these data the EC3 value was calculated to be 43.6%. On this basis
nBMA would be considered a weak skin sensitiser (Dony and 2013.
n-Butyl methacrylate: local lymph node assay in mice. Harlan
Cytotest Cell Research GmbH (Harlan CCR) Dony, 2013b).
4.2. Guinea pig assays
In common with their studies of MMA and EMA, Chung and
Giles (1977) reported the successful sensitisation of guinea pigs
to nBMA. Other investigators have been less successful. nBMA
was among a series of acrylates and methacrylates studied by
van der Walle and colleagues. In the GPMT no positive responses
were recorded when animals were challenged at 21 days, and only
2 of 10 animals displayed reactions following challenge at 35 days
(Van der Walle et al., 1982). In a slightly different guinea pig assay,
the Freunds Complete Adjuvant Test, nBMA was uniformly nega-
tive (Van der Walle et al., 1982). The GPMT data would not result
in classiﬁcation of nBMA as a skin sensitiser.
4.3. In vitro and in silico approaches
In theDPRA, nBMAwas shown to elicit a positive response, albeit
somewhat weaker than recorded for MMA (Kolle, 2013; Wiench
et al., 2013). Positive responses with nBMA were also recorded in
the LuSens assay and in the MUSST (Kolle, 2013; Wiench et al.,
2013). In common with other LAM nBMA is a direct acting Michael
acceptor electrophile and is identiﬁed as a contact allergen in rele-
vant SAR models and the OECD (Q)SAR tool box OECD, 2010.
4.4. Human studies and clinical experience
AlthoughnBMA is acknowledged to be a contact allergen, there is
no evidence that it is a strong skin sensitiser among humans. Kaner-
va et al. considered patch test results over a 10 year period with a
largenumberof (meth)acrylates. In a total of 275patientswith a his-
tory of exposure to acrylates and methacrylates only 2.5% of those
tested reacted to nBMA (Kanerva et al., 1997). In the same series
the percentage of patients that responded to MMA or EMA was in
each case 7.4% (Kanerva et al., 1997). Those data are consistent with
a review of 6 cases of patients with a history of occupational expo-
sure to methacrylates that were seen in a contact dermatitis clinic.
Only 1 of the 6 patients reacted to challenge with nBMA, whereas
3 were found to be sensitised to MMA (Holme and Statham, 2000).
Moreover, in a series of patients known to be exposed to artiﬁcial
nails none of 12 subjects patch tested with nBMA were positive. In
the same investigations 4 of 21 tested with MMA were positive,
and 2 of 13 reacted to EMA (Constandt et al., 2005).
4.5. Conclusion
The data indicate that although nBMA is a contact allergen, it
has only weak skin sensitisation potency.
5. iBMA
There is little information available on the skin sensitising
potential of iBMA.
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A single LLNA has been conducted with iBMA. Using a standard
assay, groups of mice were exposed to 25%, 50% or 100% of iBMA in
AOO. The stimulation indices recorded were, respectively, 1.78,
3.64 and 5.13. Those data translate into an EC3 value of 41.4%.
On that basis iBMA would be categorised as being a weak skin sen-
sitiser (Dony, 2013c).
5.2. Guinea pig assays
No published data on the activity of iBMA in guinea pig assays
are available, other than in the form of two toxicology reports. The
ﬁrst found iBMA to be negative in the Stevens test (a less com-
monly used guinea pig assay) (Ball et al., 1977). The second
recorded a uniformly negative response to iBMA in the GPMT
(Poole and 1980. Methacrylate d’isobutyle (MAISOBU). Test for
contact sensitisation potential in the guinea pig maximisation test.
Consultox Laboratories Ltd. (Poole et al., 1980).
5.3. In vitro and in silico approaches
To our knowledge iBMA has not been tested in the in vitro
assays systems identiﬁed previously in this article. However, like
other LAME, iBMA is a direct acting Michael acceptor electrophile,
and on that basis is identiﬁed as a contact allergen in relevant SAR
models and the OECD (Q)SAR tool box OECD, 2010.
5.4. Human studies and clinical experience
Very little information is available about the skin sensitising
activity of iBMA in humans. However, there is a report by Taylor
(1989) in which cases of adverse reactions to acrylics were inves-
tigated. Of 12 subjects patch tested with iBMA all were negative.
5.5. Conclusion
Taken together the available evidence suggests that iBMA may
be able to induce skin sensitization, but that it has only weak
potency.6. EHMA
Similarly to some other LAM there is little information available
on the skin sensitising potential of EHMA.Table 2
Contact allergy data for lower alkyl methacrylate esters (LAM).
CAS no. 80-62-6 97-63-2




QSAR tool box (Version 2.0) Positive Positive
LLNA 60–90% (weak positive) 82.6% (weak p
Guinea pig assays Positive/negative (weak) Positive (weak
Direct Peptide Reactivity Assay
(DPRA)
Positive (moderate) Positive (weak
Myeloid U-937 Skin Sensitization
Test (MUSST)
Positive Positive
LuSens assay Positive Positive
KeratinoSens™ assay Positive No data




care and dental professions)
Positive (comp
to MMA)6.1. LLNA
In a standard LLNA, animals were exposed to 25%, 50% or 100%
EHMA in AOO as the vehicle. The stimulation indices recorded
were, respectively, 1.53, 2.66 and 2.85. At no test concentration
was a stimulation index of 3 or more induced and on that basis
EHMA is classiﬁed as a non-sensitiser in the LLNA (Dony and
2013. Ethylhexyl methacrylate: local lymph node assay in mice.
Harlan Cytotest Cell Research GmbH (Harlan CCR) Dony, 2013d).
6.2. Guinea pig assays
The activity of EHMA in guinea pig assays has been somewhat
variable. Both negative and positive results have been published
in investigations using the GPMT, but even the positive responses
when observed have been of low grade (L.J. 1981. Methacrylate
de 2-ethyl hexyle (MAE2H). Test for contact sensitisation potential
n the guinea pig maximisation test. ICLS Laboratories Ltd. (Poole
et al., 1981; Clemmensen, 1984; Kanazawa et al., 1999; Allen
et al., 1999).
6.3. In vitro and in silico approaches
There are no data available on the activity of EHMA in the
in vitro test methods summarised above. In common with other
LAME, and as a direct acting Michael acceptor electrophile, EHMA
is identiﬁed as a contact allergen in SAR models and in the OECD
(Q)SAR tool box (OECD, 2010).
6.4. Human studies and clinical experience
A small series of 4 patients that had developed occupational
allergic contact dermatitis from working with dental prostheses
were examined. All responded to challenge with MMA, but none
displayed reactions following patch testing with EHMA (Kanerva
et al., 1993).
6.5. Conclusion
The data on EHMA are equivocal. This ester failed to elicit a
positive response in the LLNA, and there is an absence of evidence
revealing that EHMA is a human contact allergen. The conservative
conclusion is that EHMA may have some potential to cause skin
sensitisation, but that sensitising potency is very weak.
A summary of the skin sensitisation data available for LAM is









ositive) 43.6% (weak positive) 41.1% (weak positive) Negative
) Negative Negative Positive/negative
(very weak)
) Positive (weak) No data No data
Positive No data No data
Positive No data No data
No data No data No data
arable Positive (very few
cases)
Negative Negative
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The general conclusion drawn is that MMA, EMA, nBMA, iBMA
and EHMA each possess no more than weak skin sensitising
potency. The most persuasive evidence in reaching this conclusion
derives from studies using the LLNA; a method that (as discussed
above) is currently the most informative with regard to assessment
of skin sensitising potency. In one case (EHMA) the LLNA was neg-
ative, and in the other 4 instances, where a positive result was
obtained (MMA, EMA, nBMA and iBMA), EC3 values were never
less than 40%, indicating weak skin sensitising activity. Although
guinea pig assays are usually less suitable for the assessment of
sensitising potency, the data available from these methods is, in
most instances, entirely consistent with LAM having only modest
potency. The utility of in vitro and in silico methods for potency
assessment is still unproven and uncertain, but what data are
available for LAM from such methods does not contradict conclu-
sions drawn from LLNA data. In the context of exploring the skin
sensitising activity of these (or other) chemicals the potential value
of the currently available in vitro methods is not that they provide
readouts that are necessarily of direct relevance for potency assess-
ment, but rather that those which employ cells or cell lines of
human origin may arguably provide another perspective of sensi-
tising potential in humans. Finally, although the evidence available
from clinical experience indicates that the LAM can cause skin sen-
sitisation they cannot be regarded as potent contact allergens.
There is no information deriving from clinical reports that is incon-
sistent with the categorisation of LAM as having no greater than
weak sensitising potency.8. Factors that may limit the skin sensitising potency of LAM
If the conclusion drawn is that, as a class, LAM has only weak
skin sensitising activity, then it is instructive to consider brieﬂy
the possible mechanistic basis, or bases, for this.
One general factor that is believed to inﬂuence reactivity and
skin sensitising potential is chemical structure. It has been sug-
gested that the modest sensitising activity of methacrylates is
attributable to the a-methyl substitution of the a-b double bond
that in turn destabilises the Michael transition state reducing
capacity to react with glutathione and protein-SH groups (Greim
et al., 1995; Patlewicz et al., 2007). This is in contrast to the situa-
tion that pertains to the structurally related acrylates that show
rates of glutathione reactivity that are at least two orders of mag-
nitude higher than seen with the methacrylates (McCarthy et al.,
1994), and stronger reactivity in guinea pig assays (Greim et al.,
1995), and the LLNA (Dearman et al., 2007).
The effective acquisition of skin sensitisation requires highly
orchestrated, and very complex, cellular and molecular interac-
tions that combine to elicit a T lymphocyte response of the quality
and vigour required to cause immunological priming to the induc-
ing allergen (Martin et al., 2011; Kaplan et al., 2012; Kimber et al.,
2012; Ainscough et al., 2013). Despite that complexity, it is possi-
ble to identify some critical events or processes on the pathway to
skin sensitisation. It has been proposed previously that, in effect,
there are a number of ‘hurdles’ that must be negotiated success-
fully if topical exposure to a chemical is going to result in skin sen-
sitisation. The corollary is that if such hurdles are not negotiated
successfully then sensitisation will not be acquired, or at least will
be acquired less effectively (Kimber et al., 2011; Jowsey et al.,
2006; Kimber and Dearman, 2003).
Those events and processes that have been identiﬁed as being
on the critical path to skin sensitisation are: (a) the chemical gain-
ing access to the viable epidermis, (b) the formation of stable hap-
ten-protein conjugates, (c) the elicitation of ‘danger’ signals in theskin that support the activation of cutaneous DC which in turn are
responsible for the recognition, processing and transport of antigen
to regional lymph nodes, and its subsequent presentation to
responsive T lymphocytes, and (d) the proliferation and clonal
expansion of allergen-responsive T lymphocytes (Kimber and
Dearman, 2003).
There are in vitro and, in some instances, in silico, models that
seek to identify contact allergens as a function of the ability of
chemicals to accomplish one of these tasks along the critical path-
way to skin sensitisation (Kimber et al., 2011; Jowsey et al., 2006).
Although, in most part, such tests have been designed for the
purposes of hazard identiﬁcation, it has been proposed that the
activity of chemicals in some of these assays could, in principle
at least, contribute to an assessment of sensitising potency
(Jowsey et al., 2006). The argument is that the level of activity
in vitro tests, and/or quantitative aspects of Q(SAR), might inform
assessment of sensitisation potency. Although, in theory, the argu-
ment is rational, it must be acknowledged that with many end-
points used in such assays it is difﬁcult to identify what speciﬁc
metrics might be most relevant in terms of potency assessment,
or indeed whether or not certain endpoints have any quantitative
relationship with the effectiveness of skin sensitisation (Jowsey
et al., 2006). Moreover, there is currently no clear view about
which events on the pathway to acquisition of skin sensitisation
play the most inﬂuential roles in determining potency. Although
there is no doubt that the vigour and quality of T lymphocyte
responses provoked by exposure to chemical allergen correlate clo-
sely with the extent to which sensitisation will develop, it is not
known which of the many events that lead ultimately to T lympho-
cyte activation and proliferation determine how strong that
response will be (Kimber et al., 2012).
In this context, in a recent examination of 3 in vitro test meth-
ods (DPRA, MUSST and KeratinoSens) the investigators reviewed
the value of these approaches not only for hazard identiﬁcation,
but also for potency assessment (Kimber and Dearman, 2003).
Although they acknowledged that currently the LLNA provides
the most accurate evaluation of skin sensitising potency, they
found that each of the 3 in vitromethods considered had, to a vary-
ing degree, some association with potency as judged by the LLNA.
However, they pointed out also that such associations were far
from perfect, and that the data showed a signiﬁcant degree of
spread between potency classes (Natsch et al., 2013).
Nevertheless, despite those limitations, it may be legitimate to
draw the conclusion that a chemical which fails to negotiate suc-
cessfully any one of these requirements or hurdles would lack
the ability to induce skin sensitisation, or would do so only ineffec-
tively (Jowsey et al., 2006).
Against that background, and acknowledging the caveats sum-
marised above, it is relevant to consider brieﬂy the activity of
LAM in test methods that have been designed to reﬂect in vitro
or in silico certain key events in the development of skin sensitisat-
ion. The tests that will be considered here are: (a) prediction in
silico of dermal absorption, (b) peptide binding assays and other
methods designed to evaluate electrophilicity, (c) activation of
DC or DC-like cells or cell lines, and (d) the activation in vitro of
primary T lymphocyte responses.
8.1. Prediction in silico of dermal absorption
In a series of comparative analyses the dermal permeability of
LAM was determined using a (Q)SAR approach based primarily
on the octanol:water partition coefﬁcient (log P), together with
consideration of molecular weight and saturated aqueous solubil-
ity. The approach used was based on an established model
described by Potts and Guy (1992). Chemicals were then ranked
according to predicted ﬂux through the skin measured in units of
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were each categorised as having moderate dermal absorption
properties (in the rank order of MMA > EMA > iBMA > nBMA).
Ethylhexylmethacrylate (EHMA) was classiﬁed as having low der-
mal absorption (Heylings, 2013). These results would be consis-
tent, possibly, with EHMA having lesser skin sensitising potency
that other LAM.
8.2. Peptide binding assays
As indicated above, the LAM are intrinsically electrophilic and
would be expected, therefore, to elicit positive responses in the
DPRA. This is the case for those LAM that have been tested in this
assay: MMA, EMA and nBMA. In one series of experiments the lev-
els of reactivity (measured as a function of mean depletion of Cys
and Lys peptides) was comparable for MMA, EMA and nBMA being,
respectively, 29.5%, 10.7% and 18.6% (Kolle, 2013). The results, as
would be expected, reﬂect the fact that LAM are direct Michael
acceptor electrophiles and have the inherent potential to form sta-
ble associations with peptides and proteins, primarily through
interaction with Cys residues, but also – to a lesser extent – with
Lys. As indicated above, it is for this reason that LAM are positive
in SAR models and the OECD (Q)SAR tool box (OECD, 2010). This
property is also the basis for the positive responses seen with
MMA, EMA and nBMA in the LuSens assay (Kolle, 2013; Wiench
et al., 2013).
8.3. Activation of DC or DC-like cells or cell lines
In the better characterised DC-based assays (MUSST and
h-CLAT) those LAM that have been tested have elicited positive
responses, but these data do not provide any indication of relative
potency (Bauch et al., 2012, 2011; Kolle, 2013; Wiench et al., 2013).
8.4. Activation in vitro of primary T lymphocyte responses
Such assays seek to identify contact allergens as a function of
their ability to provoke the activation and clonal expansion of
naive allergen-responsive T lymphocytes in vitro (Richter et al.,
2013). To our knowledge LAME have not yet been tested using such
methods.
As discussed previously, the data available from in vitro test
methods and in silico models are consistent with LAM being con-
tact allergens. However, these data do not identify any one speciﬁc
characteristic that is necessarily the basis for their relatively weak
skin sensitising potency. These chemicals are natural electrophiles,
are able to gain access to the viable epidermis, and activate DC-
type cells in vitro.
In the cause of exploring what factors might serve to inﬂuence
the sensitising activity of LAM there are two other issues worthy of
consideration.
The ﬁrst of these is that it is possible that in certain circum-
stances the inherent skin sensitising activity of LAM may be aug-
mented by local inﬂammation at sites of exposure. The ‘danger
hypothesis’ proposes that the initiation of adaptive immune
response is facilitated by, and sometimes dependent upon the
receipt of endogenous or exogenous signals that indicate microbial
invasion and/or tissue disruption. It is believed that such danger
signals are relevant also for the elicitation of cutaneous immune
responses and the acquisition of sensitisation (Kimber et al.,
2002). There is an increasing appreciation of the nature of the sig-
nals relevant for skin sensitisation (Martin et al., 2011; Ainscough
et al., 2013). It is now well established that irritant dermatitis asso-
ciated with (meth)acrylates and other agents is not uncommon
among healthcare workers, including dental technicians
(Rustemeyer and Frosch, 1996; Wrangsjo et al., 2001; Nettiset al., 2002). It is possible that in some of these individuals the
acquisition of skin sensitisation to LAM in the workplace may be
facilitated by local irritation and inﬂammation that augments
immunological priming.
The second issue is the possibility that cross-reactivity plays a
role in contact allergic reactions to LAM. More than 130 potential
chemical allergens have been identiﬁed among materials used in
dental practice (Kanerva et al., 1995). From among these the
methacrylates most commonly implicated as contact allergens
are 2-hydroxyethyl methacrylate (2-HEMA) and ethyleneglycol
dimethacrylate (EGDMA) (Kanerva et al., 2001; Isaksson et al.,
2005). As cross-reactivity between methacrylate esters has been
observed in studies using experimental animals (Chung and
Giles, 1977; Van der Walle and Bensink, 1982), it is possible that
some at least of patch test reactions to LAM result from sensitisat-
ion to other methacrylate esters.
The conclusion drawn is that the modest sensitising potency of
LAM is likely due to a combination of a variety of factors, including
possibly only moderate skin permeability and low overall immu-
nogenicity. Whatever the root causes, the information available
from the LLNA is that LAM are weak skin sensitisers, and the data
available from other test methods, and from other sources, is con-
sistent with that view. It is possible that, despite this inherent
weak sensitising potential, the development of sensitisation to
LAM may be facilitated in some occupational settings by pre-exist-
ing eczema. Finally, it must be borne in mind that at least some
cases of reactivity to LAM could result from initial sensitisation
to other methacrylates and immunological cross-reactivity.9. Exposure to lower alkyl methacrylate esters
Acrylic resins are thermoplastic materials produced by the poly-
merisation ofmethacrylic acid esters (methacrylates) or acrylic acid
esters (acrylates). Methyl methacrylate monomer (MMA) is by far
the most important methacrylic acid ester. As summarised above,
in 2011 global manufacture of polymethyl methacrylate (PMMA)
resins was estimated to be almost 3 million metric tons, production
being in China, USA, Western Europe, Japan, Korea and Singapore
with the principal consumption occurring in North America, China,
Western Europe and Japan (Chemical Economics Handbook, 2012).
There are no deﬁnitive data available for the global production and
consumption of other LAM, but reasonable estimates are as follows:
EMA 10,000 tons, nBMA 140,000 tons, iBMA 140,000 tons and
EHMA 10,000 tons. Much of LAM production is destined for manu-
facture of acrylic homo-polymers, although there is some copoly-
merisation with other non-acrylate monomers and compounding
with additives to produce a wide range of acrylic-based polymers.
In 2011, productionwas divided between themanufacture of acrylic
sheet (32%) (including cast and extruded), moulding compounds
(32%), surface coatings (20%), impact modiﬁers/processing aids
(5%), with a further 13% used for the production of acrylic latexes
(emulsions), lacquers, enamels, powder coating resins andmodiﬁed
alkyd resins (Chemical Economics Handbook, 2012) Some LAM pro-
duction ﬁnds application in the manufacture of monomer/polymer
basedsystemsaimedat relatively small-volumenichemarkets, such
as the building industry (reactive resins and paints), medical (bone
cements), dental (denture manufacture and repair), and arts and
crafts (cements and embedment systems). Methacrylate mono-
mer/polymer based systems are also used in artiﬁcial nails (acrylic
nails and ﬁllers etc.). Historically, this application used MMA exclu-
sively, but since the US Food and Drug Administration (FDA) intro-
duced a ban on nail products containing 100% MMA monomer in
1974 (FDA et al., 2010), and in the absence of regulations that specif-
ically prohibit the use of MMAmonomer at lower concentrations in
cosmetic products, it continues to be found in nail products in the
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2009). Increasingly, EMA is the LAM preferred by the cosmetology
industry. This is despite this application, and indeed any application
with unavoidable direct skin or nail contact, not being supported by
the monomer manufacturers (MPA, 2014).
In terms of potential for worker exposure, LAM are exclusively
manufactured by industry on large scale manufacturing sites. Since
the processes involve the use of highly toxic raw materials, such as
hydrogen cyanide, they are subject to hazard regulations so there is
an assumed high level of safety awareness and compliance with
recommended control measures. Methacrylate based polymers
are also almost exclusively manufactured either in large scale
semi-closed systems, such those used for the production of sheet
products, or in medium to large scale batch processes, such as
those used for the production of moulding compounds or latexes.
The numbers of workers involved in these activities are relatively
small when compared with those in downstream industries han-
dling polymers, and mechanical control measures combined with
the use of personal protective equipment can avoid skin exposure
to liquid monomers (EU, 2010). Such assumptions cannot be neces-
sarily made for all skilled trade and professional workers handling
monomer/polymer based products since compliance with recom-
mended handling practices may be less consistent.
In the dental industry there are some 200,000 registered dental
technicians in North America and Europe [USA: 40,900 (States
Department of Labor, 2013); Canada, 850 (Canadian Government,
2013) and EU/EEA [27 counties of the EU, Iceland, Liechtenstein,
Norway, Switzerland and Croatia], 150,189 (EU, 2013), and a further
(approximately) 700,000 dental assistants [USA > 300,000 (BLS,
2013a); EU/EEA, 400,000 (EU, 2013)]. In terms of awareness and
compliance with safe handling practices, there is in the USA no for-
mal requirement for a vocational qualiﬁcation to become a dental
technician, although there is an entry requirement for a high school
diploma, or equivalent, and moderate-term on-the-job training.
There is only a post-secondarynon-degree award entry requirement
to become a dental assistant. In Canada, dental technologists and
technicians must have a college diploma in dental prostheses tech-
nology (formerly dental technology) and dental laboratory bench
workers require a high-school diploma. Within the EU/EEA there is
a requirement for registration with a Competent Authority follow-
ing formal vocational training andqualiﬁcation in 23 countries,with
overseas training required by 2 (Cyprus and Liechtenstein). Training
is generally of two to ﬁve years duration and takes place in special
schools, sometimes but not always, associated with dental schools;
and often follows training as a dental chair-side assistant or dental
technician. In the remaining 9 countries (Croatia, Czech Republic,
Denmark, France, Ireland, Luxembourg, Netherlands, Poland and
Spain (although technician registration is mandatory in some
regions) formal training is available, but there is no requirement to
register with a Competent Authority (EU, 2013).
In the case of cosmetology, there were more than 62,000 mani-
curists and pedicurists in the USA in 2012 (BLS, 2013b) associated
with an estimated annual revenue from nail services in 2013/13 of
over $7 billion (Industry Statistics Highlights, 2013). There is an
entry level requirement for a post-secondary non-degree to become
amanicurist and pedicurist, followedby a state-approved cosmetol-
ogy program (BLS, 2013b). After the program is completed, all states
except Connecticut require that a state examination is passed before
a license is awarded. Statistics arenot available for theEU/EEA. There
are no formal national registers of nail technicians and training is
either through National Vocational Qualiﬁcations (NVQ), short
training courses, or on-the-job training.
There are apparently no organisations collecting statistical data
for the other uses such as the building industry, and as a conse-
quence analyses for these sectors cannot be conducted.In terms of standards and practices in skilled trade and profes-
sional workers handling monomer/polymer based products it may
be concluded that there are established standards of occupational
hygiene practice, including the use of personal protective equip-
ment such as gloves, within the dental industry; although these
standards may not necessarily be uniformly applied in all coun-
tries. In the cosmetology industry there may well be established
standards and practices within the USA, but this may not extend
to Europe and other countries. Furthermore, since this use involves
direct application of liquid LAM to the nails of customers, with the
opportunity for coincidental skin contact, these standards and
practices apply only to the cosmetology worker. For other skilled
trade and professional uses, other than recommended handling
practices, warnings and directions on products, no conclusion can
be drawn regarding adoption of skin protection to avoid contact
allergy due to LAM.
With respect to polymerised LAM, once polymerised, the levels
of residual acrylic monomers in the polymer are extremely low
(Pemberton and Lohmann, 2014). Therefore, although there are
likely to be far greater numbers of individuals (both workers and
consumers) exposed to these articles and polymer-based products,
there is no concern for contact allergy during normal handing.
10. Risk assessment
It is clear that the available toxicological and clinical data sup-
port the conclusion that LAM are contact allergens, but importantly
have only weak skin sensitisation potential. There is evidence of
occupational ACD occurring in the dental industry but the reported
number of cases compared with the extremely large numbers of
individuals working in this industry would point to the actual
prevalence being very low indeed (for example between 0.24%
and 0.38% for MMA), and consistent with LAM being weak skin
sensitisers. The reports of ACD and nail reactions in consumers of
the cosmetology industry are not surprising since this use can
involve direct application of the liquid LAM to the nail, and avoid-
ing contact with surrounding skin cannot be guaranteed. Although
statistics for this industry are not available, and there is an impres-
sion that the prevalence of adverse reactions may again be low
compared with the scale of the industry, such uses are on principal
advised against. Although there are no data available on the stan-
dards and practices in other industries handling liquid LAM there is
no evidence in the literature that this is a problem that warrants
special consideration. On this basis the conclusion drawn is that
cases of occupational ACD reported in the literature are commonly
the result of extended and intimate exposure to the inducing
methacrylate ester. It is the case that even weak contact allergens
will induce skin sensitisation if the extent and duration of exposure
is sufﬁcient.
11. Conclusion
MMA and other LAM are weak skin sensitising chemicals and
should be categorised as such. Detailed evaluation of the sensitis-
ing properties of, and exposure patterns to, this series of chemicals
illustrates the importance of considering carefully apparently
inconsistent data in reaching decisions about categorisation on
the basis of potency. In particular it is necessary to distinguish
carefully between true skin sensitising potency and estimates of
the prevalence of ACD deriving from clinical experience.
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